Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780975 · ClinicalTrials.gov registry record · Phase 2
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase 2 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00780975 is a Phase 2 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 8 participants.
The verdict
NCT00780975, a Phase 2 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed the informed consent will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. A detailed explanation can be provided by the investigator conducting the study.
Interventions
- DRUG Aplidin (plitidepsin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780975
The ClinicalTrials.gov registry entry for NCT00780975 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aplidin (plitidepsin) is the first listed.
NCT00780975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780975 about?
NCT00780975 is a clinical study titled "A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer". This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed the informed consent will be enrolled in the study. Participants will be required to attend regular clinic visits t...
What is the current status of trial NCT00780975?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2005-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00780975?
The interventions under investigation include: Aplidin (plitidepsin) (DRUG).
Who is sponsoring clinical trial NCT00780975?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.